A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PHASE 3 EFFICACY AND SAFETY STUDY OF PATIDEGIB TOPICAL GEL, 2%, FOR THE REDUCTION OF DISEASE BURDEN OF PERSISTENTLY DEVELOPING BASAL CELL CARCINOMAS (BCCS) IN SUBJECTS WITH BASAL CELL NEVUS SYNDROME/PROTOCOL PELLE-926-301

Registry ID

PELLE-926-301

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

PELLEPHARM, INC

Start date

2021-04-12

Completion date

2021-04-12

Last update

2018-11-02

Conditions

• BASAL CELL NEVUS SYNDROME

View on source registry